Inhaled anticholinergics: increased risk of major adverse CV events? News item 19 January 2013 Pages: 3 - 3
EMEA's CHMP has recommended updating the product information for natalizumab [Tysabri] to further increase the awareness about risk of progressive multifocal leukoencephalopathy (PML) Media release 19 January 2013 Pages: 4 - 4